Page 34 - GPD-2-3
P. 34

Gene & Protein in Disease                                           Signatures construction strategies for TC



            4. Discussion                                      Data collection and curation: Jing Chen, Han Wang,
                                                                  Mengke Li
            In the present review, we conducted a systematic review   Software: Yingying Lian, Xinyu Li, Binbin Zhao
            and an integrated analysis of previously reported prognostic   Project administration: Xiaoqing Wang
            signatures for TC. By comprehensive analysis, we summed   Funding acquisition: Xiaoqing Wang, Yang An
            up the construction processes of prognostic signatures   Validation: Yufei Jiang, Bingbing Guo, Wenyuan Lu, Shijia
            for TC, classified the reported prognostic signatures, and   Li, Jiahao Chen
            summarized three main strategies for signature construction.
                                                               Writing – original draft: Xiaoyan Lu, Yuanyuan Zhang,
              In particular, strategy 1 mainly focused on DEGs; strategy   Writing – review & editing: Yang An
            2 confined  the scope of signatures to  specific  biological
            functions, such as immune-related and ferroptosis-related   Ethics approval and consent to participate
            genes [22,25,26,80] ,  making  these  signatures  more  targeted  to   Not applicable.
            TC treatment; and strategy 3 mainly focused on epigenetic
            methylation, providing a new research direction for the   Consent for publication
            prognosis of TC patients [47-49] . Among these, strategy 1 is
            the most extensive and common method of prognostic   Not applicable.
            signature establishment. In addition to common types of   Data availability
            prognostic  signatures,  plenty  of  signatures  in  the  forms
            of ncRNAs, carbohydrate metabolism, and alternative   The data supporting that this systematic review was
            splicing were explored as indicators of risk assessment [64,81] .  derived from previously reported studies, which were
                                                               collected from the PubMed database and had been cited.
              To summarize, this review provides a comprehensive   The processed data are available from the corresponding
            understanding, systematic summary, and integrated   author on request.
            analysis of prognostic signatures for TC, which may help
            researchers further understand cancer progression and    References
            predict the recurrence risk of TC to improve the life quality
            of TC patients.                                    1.   Antonelli A, La Motta C, 2017, Novel therapeutic clues in
                                                                  thyroid carcinomas: The role of targeting cancer stem cells.
            Acknowledgment                                        Med Res Rev, 37(6): 1299–1317.

            None.                                                 https://doi.org/10.1002/med.21448
                                                               2.   Tofe S, Arguelles I, Forteza A, et al., 2023, Age-standardized
            Funding                                               incidence,  mortality  rate,  and  trend  changes  of  thyroid
                                                                  cancer in the Balearic Islands during the 2000–2020 period:
            This work was supported by the Program for Science    A population-based study. Eur Thyroid J, 12(3): e220183.
            and Technology Development in Henan Province
            (No.212102310616); Innovation Project for College      https://doi.org/10.1530/ETJ-22-0183
            Students of Henan University (No.20237003001;      3.   Gonzalez-Clavijo AM, Cuellar AA, Triana-Urrego J,
            20237003002; 20237003003; 202310475091; 20231022022);   et al., 2023, Metastatic differentiated thyroid cancer: Worst
            the Natural Science Foundation of Henan Province      prognosis in patients with metachronous metastases.
            (No.232300421301); and the Program for Science and    Endocrine, 81(1): 90–97.
            Technology Development in Kaifeng City (No.2203009).     https://doi.org/10.1007/s12020-023-03302-0

            Conflict of interest                               4.   La Vecchia C, Malvezzi M, Bosetti C, et al., 2015, Thyroid
                                                                  cancer mortality and incidence: A  global overview.  Int  J
            The authors declare they have no competing interests.  Cancer, 36(9): 2187–2195.

            Author contributions                                  https://doi.org/10.1002/ijc.29251
            Conceptualization: Yang An                         5.   Araque KA, Gubbi S, Klubo-Gwiezdzinska J, 2020, Updates
            Investigation: Wenyuan Lu, Shijia Li, Jiahao Chen, Yingying   on the management of thyroid cancer.  Horm  Metab  Res,
                                                                  52(8): 562–577.
               Lian, Xinyu Li, Binbin Zhao
            Methodology: Xiaoyan Lu, Yuanyuan Zhang, Pei Yang,      https://doi.org/10.1055/a-1089-7870
               Minjun Yi, Luyao Wang                           6.   Chmielik  E,  Rusinek  D,  Oczko-Wojciechowska  M,
            Formal analysis: Xiaoyan Lu, Yuanyuan Zhang, Pei Yang,   et al., 2018, Heterogeneity of thyroid cancer. Pathobiology,
               Minjun Yi, Luyao Wang, Yufei Jiang, Bingbing Guo   85(1–2): 117–129.


            Volume 2 Issue 3 (2023)                         18                       https://doi.org/10.36922/gpd.1138
   29   30   31   32   33   34   35   36   37   38   39